A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type virus and Delta variant

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Immunology

Medicine

Microbiology

Pathology

Show all topics

DOI

10.1101/2021.06.28.450181

License

CC-BY

Other Formats

PDF